1月12日，可孚医疗涨5.24%，截至发稿，报58.49元/股，成交2.12亿元，换手率1.92%，总市值122.18亿 元。 资料显示，可孚医疗科技股份有限公司位于湖南省长沙市雨花区振华路816号,香港新界葵涌工业街23- 31号美联工业大厦22楼B单元，成立日期2009年11月19日，上市日期2021年10月25日，公司主营业务涉 及从事家用医疗器械的研发、生产、销售和服务。主营业务收入构成为：康复辅具类产品43.12%，医 疗护理类产品32.45%，健康监测类产品20.76%，其他(补充)3.68%。 数据显示，兴银基金旗下1只基金重仓可孚医疗。兴银智选消费混合A（018990）三季度持有股数8.38万 股，占基金净值比例为4.1%，位居第五大重仓股。根据测算，今日浮盈赚取约24.39万元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 兴银智选消费混合A（018990）成立日期2023年11月2日，最新规模1975.61万。今年以来收益3.07%， 同类排名48 ...

中午，王先生去家附近的社区食堂吃饭，饭后他打算再去社区养老驿站适老化样板间体验一下。他坦言，他也是体验了多次才慢慢觉得要进行 家居改造。 来到这个样板间，看到的不仅仅简单的家居装修，也不仅仅是这个单一的适老化产品，而是整个为老年人量身打造的"安全舒适港湾"。 对老年人来说，家是最安全舒适的港湾。当弯腰、起身、开关门这些小事渐渐变得费力，一处小小的适老化改造，就能给日常起居带来不少的 舒适便捷。 央视网消息：截至2024年底，我国60岁及以上人口达到3.1亿人，银发消费市场规模庞大。随着养老服务体系越来越成熟，内涵持续拓展深 化，当前我国养老服务正从保障基本安全与照护，向促进精神丰盈、社会参与延伸。 北京的王先生今年已经75岁了，平时爱锻炼，生活规律健康。但随着年龄的增长，他对居家生活的便利性和安全性有了更高的要求，全屋适老 化改造的想法也逐渐在他心中成型。 除了家装的适老化改造之外，各种健康监测类产品也吸引了不少老人。 老人们的点赞也印证了这些适老化改造的吸引力。改造又是如何诞生的？如何设计以及如何考量的？ 中国建筑设计研究院有限公司高级工程师马哲雪介绍，这是实验室，平时做一些实验检测，一些产品的设计。工作人 ...

（央视财经《经济信息联播》）截至2024年底，我国60岁及以上人口达到3.1亿人，银发消费市场规模 庞大。随着养老服务体系越来越成熟，内涵持续拓展深化。当前，我国养老服务正从保障基本安全与照 护，向促进精神丰盈、社会参与延伸。 总台央视记者 范紫霄：对老年人来说，家是安全舒适的港湾，当弯腰、起身、开关门这些小事逐渐变 得费力，一处小小的适老化改造，就能为日常起居带来不少舒适、便捷。 北京的王先生今年已经75岁了，平时爱锻炼，生活规律健康，但随着年龄的增长，他对居家生活的便利 性和安全性有了更高的要求，全屋适老化改造的想法也逐渐在他心中成型。 中午，王先生去家附近的社区食堂吃饭，饭后，他打算再去社区养老驿站适老化样板间体验一下。他坦 言，他也是体验了多次，才慢慢觉得要进行家居改造。 北京某健康管理有限公司设计总监 李健：合作的厂商也会为他们提供一手的数据。他们在研发、生产 的过程中都会有一定的侧重，能够刺激到他们的产品与市场相互联系，（适老化产品）需求量逐年在增 加。 总台央视记者 范紫霄：来到这个样板间，我们看到的不仅仅是简单的家居装修，也不仅仅是单一的适 老化产品，而是整个为老年人们量身打造的"安全舒适港湾 ...

12月23日，可孚医疗涨0.33%，成交额5890.77万元。两融数据显示，当日可孚医疗获融资买入额 1618.65万元，融资偿还1152.22万元，融资净买入466.43万元。截至12月23日，可孚医疗融资融券余额 合计1.21亿元。 融资方面，可孚医疗当日融资买入1618.65万元。当前融资余额1.20亿元，占流通市值的1.26%，融资余 额超过近一年70%分位水平，处于较高位。 责任编辑：小浪快报 截至12月19日，可孚医疗股东户数1.60万，较上期减少5.88%；人均流通股12140股，较上期增加 6.25%。2025年1月-9月，可孚医疗实现营业收入23.98亿元，同比增长6.63%；归母净利润2.60亿元，同 比增长3.30%。 分红方面，可孚医疗A股上市后累计派现12.35亿元。近三年，累计派现9.78亿元。 机构持仓方面，截止2025年9月30日，可孚医疗十大流通股东中，国泰医药健康股票A（009805）退出 十大流通股东之列。 融券方面，可孚医疗12月23日融券偿还800.00股，融券卖出3500.00股，按当日收盘价计算，卖出金额 15.96万元；融券余量2.30万股，融券余额104.90 ...

Group 1 - The core viewpoint of the news is that Kewei Medical has seen a stock price increase of 5.23%, reaching 42.05 CNY per share, with a total market capitalization of 8.784 billion CNY [1] - Kewei Medical, established on November 19, 2009, specializes in the research, production, sales, and service of home medical devices, with its main revenue sources being rehabilitation aids (43.12%), medical care products (32.45%), health monitoring products (20.76%), and others (3.68%) [1] Group 2 - Tianhong Fund has a significant holding in Kewei Medical, with Tianhong Zhenxuan Health Mixed A (014708) reducing its stake by 41,900 shares, now holding 172,400 shares, which constitutes 6.91% of the fund's net value, ranking as the fifth-largest holding [2] - The Tianhong Zhenxuan Health Mixed A fund has achieved a year-to-date return of 33.2%, ranking 2108 out of 8161 in its category, and a one-year return of 23.59%, ranking 3302 out of 8015 [2]

Group 1 - On October 9, Kefu Medical experienced a decline of 2.31% with a transaction volume of 55.18 million yuan, and the financing net purchase amounted to 4.30 million yuan [1] - As of October 9, the total balance of margin trading for Kefu Medical reached 115 million yuan, with a financing balance of 114 million yuan, accounting for 1.42% of the circulating market value [1] - The company repaid 3,900 shares of securities lending on October 9, with a remaining securities lending balance of 80.64 million yuan, which is above the 80th percentile level over the past year [1] Group 2 - As of September 30, Kefu Medical had 17,000 shareholders, a decrease of 10.53%, while the average circulating shares per person increased by 11.76% to 11,426 shares [2] - For the first half of 2025, Kefu Medical reported a revenue of 1.496 billion yuan, a year-on-year decrease of 4.03%, and a net profit attributable to shareholders of 167 million yuan, down 9.51% year-on-year [2] Group 3 - Since its A-share listing, Kefu Medical has distributed a total of 1.235 billion yuan in dividends, with 978 million yuan distributed over the past three years [3] - As of June 30, 2025, Kefu Medical's ninth largest circulating shareholder is Guotai Medical Health Stock A, holding 2.3012 million shares, an increase of 236,600 shares compared to the previous period [3]

Group 1 - On September 25, Kefu Medical experienced a decline of 1.43% with a transaction volume of 81.23 million yuan [1] - The financing data on the same day showed a financing purchase amount of 6.12 million yuan and a financing repayment of 9.68 million yuan, resulting in a net financing outflow of 3.56 million yuan [1] - As of September 25, the total balance of margin trading for Kefu Medical was 126 million yuan, with a financing balance of 125 million yuan, accounting for 1.55% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of August 29, the number of shareholders for Kefu Medical was 19,000, with an average of 10,223 circulating shares per person, showing no change from the previous period [2] - For the first half of 2025, Kefu Medical reported an operating income of 1.496 billion yuan, a year-on-year decrease of 4.03%, and a net profit attributable to the parent company of 167 million yuan, down 9.51% year-on-year [2] Group 3 - Kefu Medical has distributed a total of 1.235 billion yuan in dividends since its A-share listing, with 978 million yuan distributed over the past three years [3] - As of June 30, 2025, among the top ten circulating shareholders of Kefu Medical, Guotai Medical Health Stock A ranked as the ninth largest shareholder with 2.3012 million shares, an increase of 236,600 shares from the previous period [3]

Group 1 - The core viewpoint of the news is that Kefu Medical has experienced a decline in stock price and trading volume, with significant net financing outflows on September 15 [1] - As of September 15, Kefu Medical's financing balance is 1.50 billion yuan, with a net financing outflow of 815.54 million yuan for the day [1] - The company has a high financing balance, accounting for 1.80% of its market capitalization, which is above the 90th percentile level over the past year [1] Group 2 - Kefu Medical's revenue for the first half of 2025 is reported at 1.496 billion yuan, a year-on-year decrease of 4.03%, while the net profit attributable to shareholders is 167 million yuan, down 9.51% year-on-year [2] - The company has distributed a total of 1.235 billion yuan in dividends since its A-share listing, with 978 million yuan distributed in the last three years [3] - As of June 30, 2025, Kefu Medical's top ten circulating shareholders include Guotai Medical Health Stock A, which increased its holdings by 236,600 shares [3]

Core Viewpoint - Company Kefu Medical has submitted an application for listing on the Hong Kong Stock Exchange, aiming for a dual listing after its previous listing on the Shenzhen Stock Exchange in 2021 [3][4]. Company Overview - Kefu Medical is one of the largest home medical device companies in China, established in 2007, focusing on providing convenient solutions for consumers and patients seeking high-quality home medical devices [3][5]. - The company has significant competitive advantages in various verticals of the home medical device industry, ranking second among all home medical device companies in China based on projected domestic revenue for 2024 [3][5]. Financial Performance - For the six months ending June 30, 2025, Kefu Medical reported revenue of approximately 1.496 billion RMB, a year-on-year decrease of about 4.0%, and a net profit attributable to shareholders of approximately 167 million RMB, down 9.5% year-on-year [3][4][14]. Fundraising Purpose - The net proceeds from the IPO are intended for global expansion, ongoing product research and technological innovation, including applications of artificial intelligence and the Internet of Things, expanding domestic sales channels and distribution networks, brand promotion, and general corporate purposes [4][5]. Product Strategy - Kefu Medical strategically focuses on five categories of home medical devices with strong growth potential: rehabilitation aids, medical care products, traditional Chinese medicine therapy products, health monitoring products, and respiratory support products [6][16]. - The company offers a comprehensive product range with over 200 products and thousands of specifications, enhancing its position as a one-stop solution for consumers' medical needs [6][16]. Sales Network - Kefu Medical has developed a broad and deep sales network in China, with significant overseas influence, covering both online and offline channels [7][9]. - The online sales revenue reached 1.9807 billion RMB in 2024, with full coverage of major e-commerce platforms such as Tmall, JD.com, Douyin, Xiaohongshu, Pinduoduo, and Yaoshi Bang [10][11]. Market Position - According to Frost & Sullivan, Kefu Medical ranks first in the online revenue segment of the home medical device market in China for 2024 [11][12]. - The company has expanded its global footprint, reaching over 60 countries and regions across Asia, Africa, Europe, and the Americas [13].

Core Viewpoint - Kefu Medical Technology Co., Ltd. has submitted an application for a dual listing on the Hong Kong Stock Exchange, marking the official start of its A+H dual listing strategy, following its previous listing on the A-share market [1][5]. Group 1: Company Overview - Kefu Medical, established in 2007, focuses on five categories of home medical devices, including rehabilitation aids, medical care products, health monitoring devices, respiratory support products, and traditional Chinese medicine therapy products, making it one of the largest home medical device companies in China [5][6]. - According to Frost & Sullivan, Kefu Medical ranks second among all home medical device companies in China by sales revenue for 2024 [6]. Group 2: Financial Performance - Kefu Medical's revenue for the years 2022 to 2025 (first half) is approximately 2.977 billion, 2.854 billion, 2.983 billion, and 1.496 billion yuan, respectively, with a compound annual growth rate of 2.9% over the past three years [7]. - The company's net profit for the same period is approximately 302 million, 253 million, 312 million, and 167 million yuan, indicating a decline in profitability in 2023, with a further 9.5% year-on-year decrease in net profit in the first half of 2025 [8]. Group 3: Market Position and Strategy - Kefu Medical has achieved significant online sales success, with 2024 online sales reaching 1.981 billion yuan, ranking second among home medical device companies in China [10]. - The company has established a comprehensive presence on major e-commerce platforms, leveraging "Douyin + e-commerce" strategies to capture market share [11]. - Kefu Medical is actively expanding its overseas business, with international revenue accounting for only 1.98% of total revenue in 2024, but showing significant growth of over 200% in the first half of 2025 [11]. Group 4: Future Plans - The funds raised from the Hong Kong listing will primarily be used for product research and development, global sales network expansion, business development, brand marketing, and supplementing working capital [11].